Cellmid

Cellmid Limited (CDY) is an Australian life sciences accelerator for indication of multiple diseases. It operates mainly through its wholly owned subsidiaries, Advangen Limited, Kinera and Lyramid Limited, that develop and market innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss.

The company holds global intellectual properties relating to novel targets midkine and FGF5.

Contact Details

Suite 204, Level 2 , 55 Clarence Street SYDNEY NSW 2000

02 9221 6830

info@cellmid.com.au

www.cellmid.com.au

Lists and Charts

Share price

Cellmid
Closing price for the last 90 trading days

View ASX Chart

Revenue

Rank		Company	#
831^st	-	Cellmid	$6.80m

1330 public companies - non WA ranked by total revenue

View Full List

Company Share Transactions

Company Activity

	NEW ROLE: Teruko Fujii,	04 Nov 2021
	NEW ROLE: Sarah Eck-Thompson, Alternate Director for Dennis Eck	05 Dec 2020
	NEW ROLE: Brian McGee, CEO, North America	24 Nov 2020
	NEW ROLE: Bart Wuurman, Chief Executive Officer	24 Nov 2020
	NEW ROLE: Martin Cross, Non-Executive Director	03 Nov 2020
	NEW ROLE: Lee Tamplin, Company Secretary	03 Nov 2020
	NEW ROLE: David King, Non-Executive Chair	03 Nov 2020
	NEW ROLE: Dennis Eck, Non-Executive Director	03 Nov 2020
	NEW ROLE: Bruce Gordon, Non-Executive Director, Chair since 2021	03 Nov 2020

Related Information

Access to our data for Cellmid is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Cellmid is included in 1 list - Public Companies - non WA.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

Subscribe today